GHK-Cu Research

Pickart L, Vasquez-Soltero JM, Margolina A

The comprehensive review that established GHK-Cu as a multi-pathway skin regeneration agent. The paper documents that GHK-Cu — first isolated by Pickart in 1973 when he discovered it made aged liver tissue behave like younger tissue — accelerates wound healing, improves transplanted skin take, stimulates collagen and glycosaminoglycan synthesis, attracts immune and endothelial cells to injury sites, and restores replicative vitality to fibroblasts after radiation therapy. Crucially, plasma GHK levels decline from 200 ng/mL at age 20 to 80 ng/mL by age 60 — a 60% drop that coincides with the well-documented decline in tissue regenerative capacity. The paper concludes that GHK-Cu “may be one of the few molecules with the ability to reset cellular function” toward a younger profile.

Pickart L, Margolina A

A landmark review synthesizing GHK-Cu’s known biological actions with groundbreaking gene expression data from the Broad Institute’s Connectivity Map. Using this publicly available genomic database, researchers found that GHK-Cu modulates expression of genes across an extraordinary range of categories — wound healing, collagen synthesis, anti-inflammatory signaling, nerve growth, antioxidant defense, and DNA repair. At higher concentrations it upregulated 10 caspase and caspase-associated genes with anti-cancer relevance, and combined GHK-Cu with ascorbic acid produced strong suppression of sarcoma-180 growth in mice. The paper expanded GHK-Cu’s research profile from a wound healing peptide into a potential anti-aging genomic modulator — one of the most scientifically provocative findings in peptide research.

Pickart L, Margolina A

A focused review of GHK-Cu’s applications in skin protection and cancer prevention — two applications that emerge from the same underlying mechanism of DNA repair and gene expression modulation. The paper documents how GHK-Cu’s ability to modulate 84 genes associated with DNA repair and cancer suppression could make it relevant for skin cancer prevention alongside its established role in skin regeneration and anti-aging. Human clinical trial data on topical GHK-Cu showed consistent improvements in wrinkles, skin density, and overall skin quality. The paper also documents GHK-Cu’s anti-inflammatory and antioxidant properties through its copper-binding effects on superoxide dismutase activity.

Medsci Research Group

The most current systematic review of GHK-Cu in wound healing, covering studies published between 2016 and 2025. The paper documents GHK-Cu’s role across all phases of wound repair — stimulating fibroblast migration, enhancing collagen deposition, supporting angiogenesis, and facilitating extracellular matrix remodeling. It also covers advanced formulations including GHK-Cu nanoparticle conjugates, hydrogels, and clinical derivatives (TriHex and TriHex 2.0) that improve bioavailability for wound care applications. The review notes that GHK-Cu’s small tripeptide size gives it physicochemical advantages over larger peptides — better water solubility, easier tissue diffusion, and resistance to enzymatic degradation — making it highly suitable for both topical and injectable formulations.

Leyden JJ, et al.

One of the few controlled human clinical trials of GHK-Cu — examining its use after CO2 laser skin resurfacing in 13 patients. While the study found no statistically significant reduction in post-procedure erythema between GHK-Cu and control groups, patient satisfaction was significantly higher in the GHK-Cu group (p=.04), and data suggested superior improvement in wrinkle scores in Fitzpatrick classes II and III. The mixed results reflect the challenge of measuring GHK-Cu’s multifactorial effects in small controlled trials — and underscore why larger studies are needed to formally validate what extensive preclinical and cosmetic data already suggests.